Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.19 +2.2%	$3.61	$1.24 ▼ $4.08	$845.80M	0.96	4.16 million shs	2.93 million shs
AVXL Anavex Life Sciences	$9.55 -1.3%	$10.43	$4.93 ▼ $14.44	$820.25M	0.8	1.12 million shs	670,383 shs
NRIX Nurix Therapeutics	$9.65 +1.3%	$11.49	$8.18 ▼ $29.56	$737.74M	2.14	867,164 shs	483,985 shs
PRQR ProQR Therapeutics	$2.21 +3.3%	$2.13	$1.07 ▼ $4.62	$232.51M	0.43	421,008 shs	234,775 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+2.63%	-5.45%	-18.75%	+10.25%	+116.67%
AVXL Anavex Life Sciences	+2.54%	-8.33%	-13.26%	+26.21%	+57.91%
NRIX Nurix Therapeutics	-3.15%	-9.84%	-15.29%	-4.60%	-60.06%
PRQR ProQR Therapeutics	+5.42%	+5.94%	-8.55%	+26.63%	+1.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.0065 of 5 stars	3.5	2.0	4.0	3.1	0.8	0.6
AVXL Anavex Life Sciences	3.7265 of 5 stars	3.5	1.0	4.7	2.0	0.8	0.6
NRIX Nurix Therapeutics	2.398 of 5 stars	4.4	2.0	0.0	1.4	0.8	0.0
PRQR ProQR Therapeutics	2.6315 of 5 stars	3.6	5.0	0.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.00	Buy	$6.75	111.93% Upside
AVXL Anavex Life Sciences	3.00	Buy	$44.00	362.67% Upside
NRIX Nurix Therapeutics	2.81	Moderate Buy	$28.87	199.42% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	257.14% Upside

Current Analyst Ratings Breakdown

Latest PRQR, AKBA, AVXL, and NRIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	AKBA Akebia Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
8/4/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	5.27	N/A	N/A	$0.11 per share	28.95
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.06 per share	N/A
NRIX Nurix Therapeutics	$54.55M	13.51	N/A	N/A	$7.44 per share	1.30
PRQR ProQR Therapeutics	$20.46M	11.52	N/A	N/A	$0.72 per share	3.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.17	N/A	N/A	N/A	-17.91%	N/A	-13.47%	11/6/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.57	N/A	N/A	N/A	N/A	-45.67%	-40.21%	N/A
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.46	N/A	N/A	N/A	-238.52%	-61.25%	-28.13%	11/6/2025 (Estimated)

Latest PRQR, AKBA, AVXL, and NRIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
8/7/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.61	1.98	1.84
AVXL Anavex Life Sciences	N/A	8.93	8.93
NRIX Nurix Therapeutics	N/A	6.82	6.82
PRQR ProQR Therapeutics	N/A	3.76	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AVXL Anavex Life Sciences	31.55%
NRIX Nurix Therapeutics	N/A
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
AVXL Anavex Life Sciences	11.40%
NRIX Nurix Therapeutics	7.40%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	265.14 million	257.19 million	Optionable
AVXL Anavex Life Sciences	40	85.89 million	76.10 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

PRQR, AKBA, AVXL, and NRIX Headlines

Recent News About These Companies

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages

August 20 at 2:37 AM | marketbeat.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts

August 19 at 2:39 AM | americanbankingnews.com

PRQR | ProQR Therapeutics N.V. Stock Price & News - WSJ

August 12, 2025 | wsj.com

ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital

August 9, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50-Day Moving Average - What's Next?

August 8, 2025 | marketbeat.com

ProQR Announces Second Quarter 2025 Operating and Financial Results

August 7, 2025 | globenewswire.com

ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Monaco Asset Management SAM Increases Holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR)

July 30, 2025 | marketbeat.com

ProQR Announces Upcoming Presentation at RNA Editing Summit

July 28, 2025 | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages

July 25, 2025 | marketbeat.com

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

July 12, 2025 | msn.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com

July 8, 2025 | investing.com

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3, 2025 | morningstar.comM

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, AKBA, AVXL, and NRIX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.19 +0.07 (+2.24%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 -0.01 (-0.28%)

As of 07:41 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Anavex Life Sciences NASDAQ:AVXL

$9.55 -0.13 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$9.65 +0.10 (+1.05%)

As of 05:28 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Nurix Therapeutics NASDAQ:NRIX

$9.65 +0.12 (+1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$9.64 -0.01 (-0.05%)

As of 04:10 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

ProQR Therapeutics NASDAQ:PRQR

$2.21 +0.07 (+3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$2.18 -0.03 (-1.36%)

As of 06:30 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time